EUVIMEDEUVIMED entdecken
Open Access

Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine

Jessica H Rubens, Jacqueline K Brockhurst iD, Shristi Ghimire, Jinjin Wu, Liting Liu, Jason S Villano, Rebecca J Loomis, Alexandrine Derrien-Colemyn, Tracy J Ruckwardt iD, Barney S Graham, Michael W Watson, Diane E Griffin iD und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Jessica H Rubens und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Measles virus, Measles Vaccine, Measles, Hemagglutinins, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pediatric Scientist Development Program, Mevox Ltd, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Measles-mumps-rubella (MMR) is an effective live virus vaccine against measles but can be poorly immunogenic in young infants and contraindicated for pregnant and immunocompromised persons.

Methods

We evaluated immunogenicity and protective efficacy of a novel recombinant dimeric measles virus hemagglutinin protein vaccine (rMeV) in rhesus macaques. Macaques (n = 4) in 4 experimental groups were injected at days 0 and 42 with (1) MMR/MMR; (2) rMeV/rMeV; (3) MMR/rMeV; or (4) phosphate-buffered saline (PBS)/PBS and challenged intratracheally with wild-type measles virus (MeV) 8–9 months later. Blood, nasopharyngeal (NP), bronchoalveolar lavage (BAL), bone marrow (BM), and lymph node (LN) samples were collected.

Results

All macaques that received a MeV-containing vaccine developed MeV-specific binding and neutralizing antibody titers that were similar at 169 days postvaccination, regardless of experimental group. After challenge, all unvaccinated macaques had MeV detected in samples of blood, NP, BAL, BM, and LN, and 1 developed a rash. No vaccinated macaque developed a rash or had detectable MeV in peripheral blood mononuclear cells, BM, or NP cells. However, MeV and MeV RNA were detected in BAL samples in all experimental groups, with the most virus and longest detection in rMeV-vaccinated animals.

Conclusions

Immunization with rMeV protected macaques from rash, viremia, and systemic virus spread. Therefore, rMeV is protective against MeV disease and a promising option for patients unable to receive or respond to MMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Measles virusMeasles VaccineMeaslesHemagglutinins, ViralImmunogenicity, VaccineAnimalsMacaca mulattaAntibodies, ViralAntibodies, NeutralizingVaccines, SyntheticFemaleVaccine EfficacyMale

Stichwörter der Autor:innen

MMR vaccinemeasles vaccinemeasles virusnovel vaccineprotective immunity

Substanzen

Antibodies, ViralAntibodies, NeutralizingMeasles VaccineVaccines, SyntheticHemagglutinins, Viral

Autor:innen und Institutionen

  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  • Mevox Ltd., Regent House, 316a Beulah Hill, London, SE19 3HF, United Kingdom.

ORCID-Profile: Jacqueline K Brockhurst, Tracy J Ruckwardt, Diane E Griffin, Guillaume B E Stewart-Jones

Förderung

  • Pediatric Scientist Development Program
  • Mevox Ltd
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • Vaccine Research Center
  • NICHD NIH HHS
  • NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Rubens, J. H., Brockhurst, J. K., Ghimire, S., Wu, J., Liu, L., Villano, J. S., Loomis, R. J., Derrien-Colemyn, A., Ruckwardt, T. J., Graham, B. S., Watson, M. W., Griffin, D. E., & Stewart-Jones, G. B. E. (2025). Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf244

Vancouver

Rubens JH, Brockhurst JK, Ghimire S, Wu J, Liu L, Villano JS, et al. Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf244

BibTeX
@article{Rubens2025,
  author = {Rubens, Jessica H and Brockhurst, Jacqueline K and Ghimire, Shristi and Wu, Jinjin and Liu, Liting and Villano, Jason S and Loomis, Rebecca J and Derrien-Colemyn, Alexandrine and Ruckwardt, Tracy J and Graham, Barney S and Watson, Michael W and Griffin, Diane E and Stewart-Jones, Guillaume B E},
  title = {Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf244}
}
Kostenlos starten →